Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non Operating Income (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Other Non Operating Income for 15 consecutive years, with -$3000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non Operating Income changed N/A year-over-year to -$3000.0, compared with a TTM value of $3000.0 through Jun 2025, up 104.69%, and an annual FY2024 reading of -$82000.0, down 1740.0% over the prior year.
  • Other Non Operating Income was -$3000.0 for Q3 2025 at Fennec Pharmaceuticals, down from $17000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $17000.0 in Q2 2025 and bottomed at -$38000.0 in Q1 2024.
  • Average Other Non Operating Income over 5 years is -$4000.0, with a median of -$3000.0 recorded in 2022.
  • The sharpest move saw Other Non Operating Income skyrocketed 400.0% in 2023, then tumbled 1450.0% in 2024.
  • Year by year, Other Non Operating Income stood at -$1000.0 in 2021, then tumbled by 200.0% to -$3000.0 in 2022, then skyrocketed by 166.67% to $2000.0 in 2023, then crashed by 1450.0% to -$27000.0 in 2024, then surged by 88.89% to -$3000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for FENC at -$3000.0 in Q3 2025, $17000.0 in Q2 2025, and $13000.0 in Q1 2025.